

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

1. Which of the following genes is most commonly mutated in patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN)?
 - a. FLT3
 - b. IDH1
 - c. TET2**
 - d. PAX5
2. Which of the following agents is FDA approved for the management of BPDCN?
 - a. Pivekimab sunirine
 - b. Tagraxofusp**
 - c. Blinatumomab
 - d. All of the above
3. Pivekimab sunirine targets which of the following proteins?
 - a. KRAS
 - b. TP53
 - c. CD19
 - d. CD123**
4. Tagraxofusp carries a black-box warning for which of the following potentially fatal side effects?
 - a. Capillary leak syndrome**
 - b. Cytokine release syndrome
 - c. Stevens-Johnson syndrome
 - d. Bleeding
5. Which of the following adverse events was most commonly reported by patients receiving pivekimab sunirine for BPDCN in the Phase II CADENZA trial?
 - a. Peripheral edema**
 - b. Confusion
 - c. Dysgeusia
 - d. Bruising